BioSpace News Archive

Canada’s universal, publicly funded health care system is a source of pride for Canadians.

Researchers have found a long-sought enzyme that prevents cancer by enabling the breakdown of proteins that drive cell growth, and that causes cancer when disabled.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 10:30am EDT.

Medtronic plc (NYSE: MDT), the global leader in medical technology, today introduced in select European countries the Medtronic Extended infusion set — the first and only infusion set that can be worn for up to 7 days

Ambry Genetics Corporation (Ambry), a Konica Minolta Precision Medicine (KMPM) company and a leader in clinical diagnostic testing, is honored to announce that they are the recipient of five Comparably Awards in recognition of: “Best Company Outlook,” “Places to Work in Los Angeles,” “HR Teams,” “Product & Design Teams” and “Sales Teams.”

Alimentiv Health Trust, the parent company of Alimentiv, Inc. (formerly Robarts Clinical Trials), a specialized global gastrointestinal (GI) contract research organization (CRO), and McDougall Scientific Ltd., a niche CRO, announced today the launch of AcelaBio, a commercial state-of-the-art research laboratory delivering histopathology and precision medicine services for global clinical trials.

Addition of a Key Access Stakeholder Will Provide Clients With Winning Strategies to Address Complex and Rapidly Changing Cost and Utilization Challenges

Legacy, the premier digital fertility clinic for men, announced $10M in Series A fundraising led by FirstMark Capital.

Multiply Labs, a robotics company developing automated manufacturing systems for the production of individualized drugs, announced today that it has raised $20 million in a Series A financing led by Casdin Capital. New investors Lux Capital and Pathfinder, Founders Fund’s early stage investment vehicle also participated in the round, along with seed investors Fifty Years and Garage Capital.